Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study
Assoumou S, Nolen S, Hagan L, Wang J, Eftekhari Yazdi G, Thompson W, Mayer K, Puro J, Zhu L, Salomon J, Linas B. Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. The American Journal Of Medicine 2020, 133: e641-e658. PMID: 32603791, PMCID: PMC8041089, DOI: 10.1016/j.amjmed.2020.05.029.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCommunity Health CentersCost-Benefit AnalysisCounselorsFemaleHepatitis C AntibodiesHepatitis C, ChronicHumansLife ExpectancyLiver CirrhosisMaleMass ScreeningMiddle AgedOpioid EpidemicOregonPoint-of-Care TestingQuality-Adjusted Life YearsRNA, ViralSerologic TestsUnited StatesUnited States Health Resources and Services AdministrationConceptsQuality-adjusted life yearsFederally Qualified Health CentersHepatitis C virusRNA testingOpioid epidemicQualified health centersAnti-HCV test resultsKnowledge of antibody statusProportion of patientsIncremental cost-effectiveness ratioAnti-HCV testHepatitis C casesCost-effectiveness ratioHepatitis C diseaseHepatitis C testingHepatitis C managementHealth centersClinical outcomesAntibody statusC virusCost-effectiveness studiesCirrhosis casesRapid testC diseaseC cases
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply